COMPASS Pharma SRL
The score of COMPASS Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -28 % Total assets +27 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
COMPASS Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 39,042 € | ||||
| Equity | 236,480 € | ||||
| Cash | 86,600 € | ||||
| EBITDA | 48,596 € | ||||
| Total assets | 424,901 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 04 May 2026
- Year ended 31 Dec 2024filed on 06 Jun 2025
- Year ended 31 Dec 2023filed on 07 Jun 2024
- Year ended 31 Dec 2022filed on 04 Jun 2023
- Year ended 31 Dec 2021filed on 05 Jun 2022
COMPASS Pharma's financial analysis
- Solvency55.7%sector median: 58.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of COMPASS Pharma
COMPASS Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0686.912.527
- VAT number
- BE0686912527
- Peppol
- Registered · 0208:0686912527 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 29 Dec 2017
- Registered office
- 2860 Sint-Katelijne-Waver
- Latest accounts
- 2025 · filed on 04 May 2026
- Activity
- Business and other management consultancy activities (NACE 70200)
COMPASS Pharma (SRL) has been based in Sint-Katelijne-Waver since 2017, active in: business and other management consultancy activities. For 2025, it reports a net profit of 39,042 € and equity of 236,480 €; its revenue is not published. Its solvency stands at 55.7%, below the median of its sector (58.4%).
Companies similar to COMPASS Pharma
Companies in the same business, of comparable size and area, outside its group.
- Steven Bürmann Business and other management consultancy activities Brecht · balance sheet 1,052 €
- Kantoor VAN DER Weeën Business and other management consultancy activities Lebbeke · balance sheet 419,421 €
- NDX Consult Business and other management consultancy activities Modave · balance sheet 418,501 €
- Puur Catering Business and other management consultancy activities Ghent · balance sheet 432,805 €
- Van den Eynde Management Business and other management consultancy activities Kontich · balance sheet 413,356 €
- Bielieve Business and other management consultancy activities Lochristi · balance sheet 437,280 €
- Javanom Business and other management consultancy activities Tielt-Winge · balance sheet 428,958 €
- Elvema Business and other management consultancy activities Wielsbeke · balance sheet 407,770 €
Frequently asked questions about COMPASS Pharma
What is the revenue of COMPASS Pharma?
COMPASS Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of COMPASS Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0686912527 for COMPASS Pharma, if the company is VAT-registered. Its company number (CBE) is 0686.912.527.
Where is the registered office of COMPASS Pharma?
According to the CBE register, the registered office of COMPASS Pharma is in 2860 Sint-Katelijne-Waver.
What is the equity of COMPASS Pharma?
At the close of the 2025 financial year, the equity of COMPASS Pharma amounts to 236,480 €, a solvency of 55.7% of total assets.
Who manages COMPASS Pharma?
The register lists 4 active mandates at COMPASS Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of COMPASS Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →